[使用剂量面积产物计在图像导向放射治疗中的kV平面成像过程中开发剂量管理和估计模型]
Hideharu Miura1,2, Toshiya Okazue1, Kenji Kanemoto1
1Hiroshima High-Precision Radiotherapy Cancer Center.
Nihon Hoshasen Gijutsu Gakkai zasshi
|March 4, 2026
概括
这项研究有效地测量了患者的辐射剂量,使用剂量面积产物 (DAP) 计在图像导向放射治疗 (IGRT) 中的千伏 (kV) 成像过程中有效测量患者的辐射剂量. 在未测量的条件下,二维插值准确地估计了DAP.
科学领域:
- 医学物理 医学物理
- 辐射疗法 辐射疗法
- 诊断成像 诊断成像 诊断成像
背景情况:
- 准确的患者剂量测量在图像指导放射治疗 (IGRT) 中至关重要.
- 千伏 (kV) 平面成像经常用于IGRT期间的患者定位.
- 从kV成像中量化辐射剂量对于剂量管理至关重要.
研究的目的:
- 在IGRT中的kV平面成像过程中,使用剂量面积产物 (DAP) 计测量患者暴露剂量.
- 在未测量的成像条件下使用二维立方插值估计DAP.
主要方法:
- 剂量测量是使用机载成像仪上的DAP计进行的.
- 在各种管电压 (60-140 kV) 和管电流 (2.5-20 mAs) 中测量了DAP.
- 开发了一种二维立方间波模型,用于估计未测量的参数的DAP.
主要成果:
- DAP计表显示每个mAs值的高线性 (R2=1.00).
- 在低剂量条件下,最大偏离线性为1.8%.
- 使用插值估计的DAP的相对误差在2.0%以内.
结论:
- 一个DAP表是有效的剂量管理在kV平面成像IGRT.
- 二维立方插曲为未测量的成像条件提供了准确的DAP估计.
- 这种方法提高了IGRT程序中的辐射剂量监测.
更多相关视频
相关概念视频
Dose Size and Dosing Frequency: Determination Methods
451
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
451
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
306
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
306
Dosage Regimens: Designs and Approaches
406
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
406
Estimation of k and VD of Aminoglycosides
289
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
289
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
301
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
301
Dosage Regimens: Partial Pharmacokinetic Parameters
235
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
235


